Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
By The Hill | Created at 2024-09-24 22:07:41 | Updated at 2024-09-30 15:24:56
5 days ago
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Senate Health Committee Chair Bernie Sanders (I-Vt.). Novo Nordisk chief Lars Fruergaard Jørgensen told senators Tuesday that pharmacy benefit managers (PBMs), the industry middlemen that negotiate the terms and conditions…
